Breast cancer is one of the most prevalent forms of cancer among women. Certain kinds of tumors have been found to be more aggressive and associated with less than favorable prognoses compared to others. HER2 positive tumors are a hallmark of high-risk breast cancer. Emerging molecular imaging agents join tumor-seeking antibodies and signaling radioisotopes in one radiopharmaceutical that is injected at the time of imaging in order to track and report active receptors.
One of these investigational agents, known in the lab as Cu-64 DOTA-HER3 F(ab')2, does just that by hunting down HER3, a messenger that has been shown to speak for HER2-positive cancers in multiple tissue models when used in conjunction with a scanner called a positron emission tomography (PET) imaging system. This could encourage better, more personalized care for breast cancer patients.
"HER3 is thought to be an important mediator of resistance to the HER2 inhibitors class of anti-cancer therapies, which are used to treat HER2-positive breast cancer representing approximately 20 percent of all breast cancers," said principal author
The researchers expect that it may be another year or two before the agent will reach regulatory approval and enter general clinical practice.
An estimated 232,670 new cases of invasive breast cancer will be diagnosed in women this year, according to 2014 data from the
Keywords for this news article include: Oncology, Breast Cancer, Nanotechnology,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- Criminal Investigation Opened Into James Foley's Death
- Short-Term Loans Comes at a Heavy Price
- Rocket Explodes During U.S. Test Flight
- Koch Brothers Took Genes, Money in Different Directions
- Apple Stock Bounces Back Big Time
- Is Diversity in the Eye of the Beholder?
- 'Mythbusters' Build Team Gets the Boot
- Jennifer Lopez Would Marry Again
- Florida Judge Rules in Favor of GOP Voter Map
- Obama Again Faces Tug of Military Action in Syria